Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a platform of modified vaccinia ankara virus-like particle vaccines in the United States and internationally. The company is headquartered in Smyrna, Georgia.
52W High
$0.40
52W Low
$0.01
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
3.57
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
N/A
Ownership
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
0
Float
19,929,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
6,143,000
Gross Profit (TTM)
-18,951,548
EPS (TTM)
N/A
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-6.36%
ROE (TTM) (>15% strong)
-96.90%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
1.84
Momentum
Bearish momentumValue
-0.0049
Previous
-0.0050
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025